Dermatology
| Metastatic Melanoma
Dermatology
Metastatic Melanoma

Latent paraneoplastic dermatomyositis triggered by nivolumab treatment in a patient with metastatic melanoma. Case report and literature review

book_2 Source: EADV Virtual - Poster session
calendar_today Published on Medfyle: November 2020
headphones 3 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Checkpoint inhibitors have revolutionised the treatment of advanced and metastatic melanoma, but can lead to immune-related adverse events.
  • This case looked at a patient with latent paraneoplastic dermatomyositis triggered by nivolumab treatment; diagnosis was confirmed with imaging and muscle biopsy.
  • Comparison of serum samples from pre- and post nivolumab revealed pre-existing anti-TIF1γ antibodies, highlighting the need to perform an autoimmunity panel prior to treatment with a checkpoint inhibitor.
  • Both muscular and skin improvement was achieved with pulsed methylprednisolone and six cycles of immunoglobulin.
Presenting Author
Read more arrow_downward Hide arrow_upward

Laura Serra-Garcia, MD
Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain


Feedback